vs

Side-by-side financial comparison of ASSOCIATED BANC-CORP (ASB) and MYRIAD GENETICS INC (MYGN). Click either name above to swap in a different company.

ASSOCIATED BANC-CORP is the larger business by last-quarter revenue ($383.0M vs $209.8M, roughly 1.8× MYRIAD GENETICS INC). Over the past eight quarters, ASSOCIATED BANC-CORP's revenue compounded faster (9.1% CAGR vs 1.9%).

Associated Banc-Corp is a U.S. regional bank holding company providing retail banking, commercial banking, commercial real estate lending, private banking and specialized financial services. Headquartered in Green Bay, Wisconsin, Associated is a Midwest bank with from more than 220 banking locations serving more than 100 communities throughout Wisconsin, Illinois and Minnesota. The company also operates loan production offices in Indiana, Michigan, Missouri, New York, Ohio and Texas.

Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a pati...

ASB vs MYGN — Head-to-Head

Bigger by revenue
ASB
ASB
1.8× larger
ASB
$383.0M
$209.8M
MYGN
Faster 2-yr revenue CAGR
ASB
ASB
Annualised
ASB
9.1%
1.9%
MYGN

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
ASB
ASB
MYGN
MYGN
Revenue
$383.0M
$209.8M
Net Profit
$119.6M
Gross Margin
70.0%
Operating Margin
-2.7%
Net Margin
31.2%
Revenue YoY
-0.4%
Net Profit YoY
566.6%
EPS (diluted)
$0.70
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASB
ASB
MYGN
MYGN
Q1 26
$383.0M
Q4 25
$310.0M
$209.8M
Q3 25
$305.2M
$205.7M
Q2 25
$300.0M
$213.1M
Q1 25
$285.9M
$195.9M
Q4 24
$270.3M
$210.6M
Q3 24
$329.7M
$213.3M
Q2 24
$321.8M
$211.5M
Net Profit
ASB
ASB
MYGN
MYGN
Q1 26
$119.6M
Q4 25
$137.1M
Q3 25
$124.7M
$-27.4M
Q2 25
$111.2M
$-330.5M
Q1 25
$101.7M
$-100.0K
Q4 24
$-161.6M
Q3 24
$88.0M
$-22.1M
Q2 24
$115.6M
$-36.7M
Gross Margin
ASB
ASB
MYGN
MYGN
Q1 26
Q4 25
70.0%
Q3 25
69.9%
Q2 25
71.2%
Q1 25
68.5%
Q4 24
71.7%
Q3 24
70.2%
Q2 24
69.6%
Operating Margin
ASB
ASB
MYGN
MYGN
Q1 26
Q4 25
52.6%
-2.7%
Q3 25
50.5%
-11.3%
Q2 25
46.5%
-154.5%
Q1 25
42.3%
-14.8%
Q4 24
-65.8%
-18.6%
Q3 24
32.8%
-9.4%
Q2 24
32.0%
-17.3%
Net Margin
ASB
ASB
MYGN
MYGN
Q1 26
31.2%
Q4 25
44.2%
Q3 25
40.9%
-13.3%
Q2 25
37.1%
-155.1%
Q1 25
35.6%
-0.1%
Q4 24
-59.8%
Q3 24
26.7%
-10.4%
Q2 24
35.9%
-17.4%
EPS (diluted)
ASB
ASB
MYGN
MYGN
Q1 26
$0.70
Q4 25
$0.80
$-0.09
Q3 25
$0.73
$-0.29
Q2 25
$0.65
$-3.57
Q1 25
$0.59
$0.00
Q4 24
$-1.10
$-0.47
Q3 24
$0.56
$-0.24
Q2 24
$0.74
$-0.41

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASB
ASB
MYGN
MYGN
Cash + ST InvestmentsLiquidity on hand
$149.6M
Total DebtLower is stronger
$119.9M
Stockholders' EquityBook value
$5.0B
$368.0M
Total Assets
$45.6B
$706.6M
Debt / EquityLower = less leverage
0.33×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASB
ASB
MYGN
MYGN
Q1 26
Q4 25
$149.6M
Q3 25
$145.4M
Q2 25
$74.4M
Q1 25
$91.8M
Q4 24
$102.4M
Q3 24
$99.9M
Q2 24
$97.3M
Total Debt
ASB
ASB
MYGN
MYGN
Q1 26
Q4 25
$1.0B
$119.9M
Q3 25
$594.1M
$119.5M
Q2 25
$593.5M
Q1 25
$591.4M
Q4 24
$1.4B
Q3 24
$844.3M
Q2 24
$536.1M
Stockholders' Equity
ASB
ASB
MYGN
MYGN
Q1 26
$5.0B
Q4 25
$5.0B
$368.0M
Q3 25
$4.9B
$372.8M
Q2 25
$4.8B
$388.1M
Q1 25
$4.7B
$704.9M
Q4 24
$4.6B
$701.1M
Q3 24
$4.4B
$731.7M
Q2 24
$4.2B
$740.5M
Total Assets
ASB
ASB
MYGN
MYGN
Q1 26
$45.6B
Q4 25
$45.2B
$706.6M
Q3 25
$44.5B
$728.1M
Q2 25
$44.0B
$677.3M
Q1 25
$43.3B
$1.0B
Q4 24
$43.0B
$1.0B
Q3 24
$42.2B
$1.1B
Q2 24
$41.6B
$1.1B
Debt / Equity
ASB
ASB
MYGN
MYGN
Q1 26
Q4 25
0.20×
0.33×
Q3 25
0.12×
0.32×
Q2 25
0.12×
Q1 25
0.13×
Q4 24
0.31×
Q3 24
0.19×
Q2 24
0.13×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASB
ASB
MYGN
MYGN
Operating Cash FlowLast quarter
$10.6M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASB
ASB
MYGN
MYGN
Q1 26
Q4 25
$218.1M
$10.6M
Q3 25
$158.0M
$21.1M
Q2 25
$141.5M
$-13.6M
Q1 25
$98.2M
$-16.3M
Q4 24
$207.1M
$6.6M
Q3 24
$105.1M
$700.0K
Q2 24
$113.5M
$2.6M
Cash Conversion
ASB
ASB
MYGN
MYGN
Q1 26
Q4 25
1.59×
Q3 25
1.27×
Q2 25
1.27×
Q1 25
0.97×
Q4 24
Q3 24
1.19×
Q2 24
0.98×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASB
ASB

Net Interest Income$307.2M80%
Noninterest Income$75.9M20%

MYGN
MYGN

Segment breakdown not available.

Related Comparisons